Project Grant F32AI186297
Award Date
1/22/25
Completion Date
10/31/27
Dollars Obligated
$148K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $153,056 in funding to The Washington University to conduct research on heme homeostasis in the malaria parasite Plasmodium falciparum. The research aims to identify parasite proteins involved in maintaining heme levels and explore their potential as novel antimalarial drug targets. The award period runs from July...
This $924,000 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research at Tufts University School of Medicine to study mechanisms of erythrocyte adhesion in Plasmodium falciparum malaria, a leading cause of mortality worldwide. The key objectives are to: 1) Elucidate the mechanism of knob self-assembly on the surface of infected red blood cells, which...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $832,071 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Seattle Children's Hospital to develop a universal transmission blocking vaccine (TBV) against multiple Plasmodium species that cause malaria. The project aims to characterize broadly neutralizing monoclonal antibodies (mAbs) and human naturally acquired immunity against mosquito stage antigens HAP2 and HAP2P, which can block...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,104,050 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis. The funding supports research to investigate the mechanisms by which the Plasmodium falciparum parasite impairs neutrophil function, thereby increasing susceptibility to invasive bacterial infections in malaria patients. Key objectives include identifying the molecular pathways by...
This federal Project Grant award of $791,864, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify the molecular factors that control chromatin organization and gene regulation in the human malaria parasite Plasmodium falciparum. The key objectives of the project are to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $375,000.00 to the University of South Florida to conduct research on the functions of messenger ribonucleoproteins (mRNPs) in regulating RNA metabolism in the malaria parasite Plasmodium falciparum. The key objectives of this 5-year project are to: 1) identify molecular markers and characterize the protein and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $700,288 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of South Florida. The grant, titled "Phenotype-Based Screens to Identify Genetic Factors Associated with Gametocyte Development in Plasmodium falciparum," runs from November 2024 to October 2029. The project aims to use a functional genomics approach to identify P. falciparum genes essential for the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to identify surface-exposed proteins in early mosquito-stage Plasmodium falciparum parasites and evaluate their potential as transmission-blocking vaccine (TBV) candidates. The total award amount is $3,762,999.00, with a project period from July 5, 2024 to May 31, 2029. The research will use mass...
This federal Project Grant award of $406,450.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a continuous in vitro culture system for the malaria parasite Plasmodium vivax. The key objectives are to: Efficiently produce reticulocytes (young red blood cells) to support the growth of P. vivax parasites in a custom bioreactor system. Optimize the culture conditions in the bioreactor...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $3,454,926 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The grant, awarded on July 24, 2024, will support research aimed at defining the optimal pathway from B-cell receptors (BCRs) to broadly neutralizing antibodies (bNAbs) targeting the V2-glycan or "apex" epitope of the HIV-1...